Saturday, 21 December 2024
  
Login

Australia's most trusted
source of pharma news

Saturday, 21 December 2024
News

AbbVie's first move for ADC funding

Posted 3 October 2024 AM

AbbVie is advancing plans to bring its recently acquired first-in-class antibody-drug conjugate (ADC) Elahere to Australia, with the first move being an application for a diagnostic test.

The pharma has made an application to MSAC for "immunohistochemistry testing of solid tumour tissue to determine folate receptor alpha expression status in adults with platinum-resistant ovarian cancer, for access to PBS Elahere".

To see the whole article, please login

Popular

Who got booted to the May meet?
Best company Christmas gift is...
First out the door in '25?
He's back: Ex-GM wins CEO role
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2024 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home